Advances in immunotherapy are changing the treatment landscape for non-small cell lung cancer (NSCLC), with immune checkpoint inhibitors rapidly expanding the treatment landscape in early-stage and advanced or metastatic disease. However, more awareness is needed among clinicians to remain up to date with the latest guidelines that reflect advances and approvals of these   therapies. A panel led by two expert thoracic oncologists will discuss the most recent management guidelines, the significance of selecting patients’ therapy based on PD-L1 expression, and patient-centered treatment strategies as related to special populations. The panel will also review strategies for immunotherapy before and after surgery, and management of immune-related adverse events. The patient voice will be emphasized with a pre-recorded patient vignette highlighting patient experience and challenges when having concomitant NSCLC and a chronic infection.

Program Learning Objectives:

• Review guideline updates on immunotherapy in cancer and the role of PD-L1 expression testing in guiding treatment
• Outline strategies to identify patients who can benefit from peri-adjuvant, adjuvant, or neoadjuvant treatment for NSCLC
• Evaluate the latest safety and efficacy data on ICIs for NSCLC
• Outline integration of ICIs into treatment plans and individualization of therapy for special patient populations

Faculty

Abdul Rafeh Naqash, MD

Assistant Professor of Medicine

Director of Immuno-oncology

OU Health Stephenson Cancer Center at the University of Oklahoma Health Sciences

Balazs Halmos, MD

Professor of Oncology

Montefiore Medical Center

Approximate Time to Complete: 60 minutes

Credit Available: November 25, 2024 - November 25, 2025

Developed through a collaboration between SITC and PlatformQ.